Piper Sandler Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and lowers the price target from $7 to $4.

May 10, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler's adjustment of Fate Therapeutics' price target from $7 to $4 while maintaining a Neutral rating could signal a cautious outlook on the company's short-term performance.
The reduction in price target by a reputable analyst firm like Piper Sandler, despite maintaining a neutral stance, suggests a less optimistic view on the company's near-term financial health or market performance. This could lead to negative investor sentiment and potentially impact the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100